Positives

• Patients with chronic insomnia who have exhausted conventional options describe DSIP as a low-side-effect option that occasionally improves sleep latency and efficiency.
  
  
• One patient reported modest help with sleep onset on nights when their nervous system felt overactivated.
  
  

Negatives

• Patients commonly report no clear effect, consistent with the controlled trial finding that benefit was weak and possibly placebo-driven.
  
  
• A patient reported that DSIP did nothing for sleep maintenance and they returned to other approaches.
  
  

Hurdles & Side Effects

• DSIP is not FDA-approved and the supportive trial data is decades old and small.
  
  
• Sourcing is grey-market peptide vendors, and reliable potency is hard to verify.